


# Real-World Effectiveness of Risankizumab in Crohn's Disease


## Pan-UK Multi-Centre Retrospective Cohort Study

763 patients with active CD  
across 25 UK sites



Median  
Follow-Up  
27 weeks  
(IQR 18-41)

- Median age: 39 years
- Prior Advanced Therapy: 97.8%



- ✓ **Overall Persistence:** 97.8%, 95.4% and 89.2% at 3-, 6- and 12-months
- ✓ **Clinical (HBI), CRP and FCAL remission rates (6-months):** 52% (123/236), 53% (169/319), and 44% (69/156).
- ✓ **UST naïve vs UST exposed:** No difference in unadjusted persistence rates ( $p=0.62$ ) during follow-up nor clinical remission rates at 6-months (57% vs 51%)
- ✓ **Adverse Events:** 17% of the cohort, of which 12% were serious.

Elford. et al. *Frontline Gastroenterology* 2025. DOI: 10.1136/flgastro-2022025-103449

BMJ bsg fg.bmj.com X @FrontGastro\_BMJ